Funding to accelerate growth of concierge-style private health services and Aayu’s paperless hospital infrastructure platform
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Subscribe To Our Newsletter & Stay Updated
